Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Generated $50.0 million in net revenue from sales of LUMRYZ™ ----2,300 patients on LUMRYZ as of September 30th, including 700 patients that ...
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact ...